RxDoctor Payments Data

Pankaj Gupta, MD

Otolaryngology · Durham, NCNPI 1306880992

Payments from drug & device makers

$2,546in general payments, 2019–2025

Across 62 payments — averaging $41.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intersect ENT, Inc.$618
  • Aerin Medical Inc.$420
  • Smith+Nephew$363
  • Optinose US, Inc.$259
  • Acclarent, Inc$234
  • Regeneron Healthcare Solutions, Inc.$205
  • plus $446 from 8 others

What the payments were for

  • Consulting fees$40016%
  • Food & beverage$2,13184%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,546 in reported general payments places this provider in the 75th percentile of 362 otolaryngology providers in North Carolina.

See all otolaryngology providers in North Carolina

Medicare billing

Part B allowed, 2024
$206,363
Medicare patients
359
Services billed
2,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate12$10,271
XhanceFluticasone Propionate13$8,548
Epinephrine18$3,899
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth28$3,561
Mometasone Furoate17$3,194
Ipratropium Bromide47$1,400
Fluocinolone Acetonide Oil29$1,027
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort13$757
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc14$714
Doxycycline Hyclate39$628
Cefdinir21$378
Ofloxacin14$330
Fluticasone Propionate26$288
Prednisone62$241
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$259$8,54813 claims
Hikma Pharmaceuticals USAEpinephrine$14$3,89918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 362 otolaryngology providers in North Carolina.

Other otolaryngology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →